We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration to Bring Personalized Cancer Care to Singapore

By LabMedica International staff writers
Posted on 23 Nov 2014
A German company specializing in cancer diagnosis will be extending its expertise in personalized care to the health care market in Singapore.

New Oncology (Cologne, Germany) announced recently that it has entered into a collaboration agreement with the National Cancer Centre Singapore (Singapore). More...
New Oncology will provide its NEOplus proprietary diagnostic platform for use at the [Sg] National Cancer Center.

NEOplus, which is based on next generation sequencing (NGS) technology, is an efficient, time-saving diagnostic assay that enables the parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days, NEOplus reliably and with high sensitivity detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA in all solid tumor types. The medical report generated from the NEOplus results suggests suitable targeted therapies and an individualized recommendation for treatment if actionable genetic alterations are identified. In addition to treatment options, the report also provides information on relevant clinical trials.

“We are very pleased to work with NCCS, one of the most prestigious centers for research and treatment of cancer in Southeast Asia. We are looking forward to building a productive partnership with the National Cancer Center Singapore and consider this move to be a major milestone in our international business expansion,” said Dr. Andreas Jenne, CEO of New Oncology.

Related Links:

New Oncology
National Cancer Center Singapore



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.